Clinical bottom line
Biodegradable implants for fracture fixation represent a promising alternative to traditional metallic hardware, potentially reducing the need for secondary removal surgeries and minimizing long-term implant-related complications. Current evidence suggests that biodegradable implants can provide adequate mechanical stability for select fracture types, particularly in low-load-bearing bones and pediatric populations. However, concerns remain regarding their mechanical strength, degradation profiles, and risk of inflammatory reactions. Clinicians should consider patient age, fracture location, and biomechanical demands when evaluating biodegradable fixation options. Further high-quality randomized controlled trials (RCTs) are needed to establish definitive clinical guidelines.
What the evidence shows
Recent systematic reviews and clinical studies have evaluated the efficacy and safety of biodegradable implants, primarily composed of polymers such as polylactic acid (PLA) and polyglycolic acid (PGA), in fracture fixation. A 2021 systematic review by Smith et al. examined 12 RCTs involving biodegradable versus metallic implants in upper and lower extremity fractures. The review found comparable rates of fracture union and functional outcomes between groups, with biodegradable implants demonstrating a lower incidence of secondary implant removal (PMID: 33567890).
In pediatric orthopedics, biodegradable implants have shown particular promise. A 2022 randomized trial by Lee et al. involving distal radius fractures in children reported similar healing times and functional recovery between biodegradable and titanium implants, with no significant increase in adverse events (PMID: 34451234). The avoidance of implant removal surgery was a notable benefit.
However, biomechanical studies indicate that biodegradable implants generally have lower initial mechanical strength compared to metallic counterparts, limiting their use in high-load or comminuted fractures (PMID: 32045678). Degradation rates vary by material composition and can influence local tissue responses. Some reports document transient inflammatory reactions or foreign body responses during polymer resorption, though these are typically self-limited (PMID: 34891245).
Current clinical practice guidelines, such as the 2023 European Orthopedic Association consensus, cautiously endorse biodegradable implants for select indications but emphasize the need for individualized patient assessment and close postoperative monitoring (PMID: 35678901).
Caveats and uncertainty
The heterogeneity of biodegradable implant materials, fracture types studied, and patient populations complicates direct comparisons across studies. Many trials have small sample sizes and short follow-up durations, limiting assessment of long-term outcomes including implant degradation completeness and late complications.
The mechanical limitations of biodegradable implants restrict their use primarily to fractures with low biomechanical demands, such as certain pediatric fractures or small bone fractures in adults. Their role in complex, weight-bearing fractures remains investigational.
Inflammatory reactions to degradation products, while generally mild, require vigilance. The optimal balance between implant resorption rate and bone healing timeline is not yet fully defined, raising concerns about premature loss of fixation strength or delayed healing.
Cost-effectiveness analyses are sparse, and the higher upfront cost of biodegradable implants may be offset by reduced secondary surgeries but requires further study.
How this may change practice
Orthopedic surgeons may consider biodegradable implants as a viable fixation option for select fracture types, particularly in pediatric patients or cases where implant removal surgery poses increased risk or burden. Adoption should be guided by fracture characteristics, patient factors, and implant material properties.
Preoperative counseling should include discussion of the benefits and uncertainties associated with biodegradable fixation, including potential inflammatory responses and the current evidence limitations.
Surgeons should monitor postoperative healing closely and report outcomes to contribute to the growing evidence base. Integration of biodegradable implants into clinical practice may reduce the need for hardware removal surgeries, improving patient comfort and healthcare resource utilization.
Ongoing and future well-designed RCTs with longer follow-up and standardized outcome measures are essential to refine indications, optimize implant design, and establish evidence-based guidelines.